Retatrutide (40mg)
Mechanism of Action
Retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors. This combination works in an integrated manner to reduce appetite and increase satiety, improve glycaemic homeostasis, and promote greater energy expenditure/thermogenesis via activity at the glucagon receptor.
Key Benefits
- Marked reduction in body weight in clinical studies, with high-impact results in obesity.
- Improved glycaemic control and cardiometabolic markers (e.g., inflammatory lipids and blood pressure reported in readouts).
- Reduction in liver fat and improvements associated with metabolic liver disease (MASLD/MASH) in a Phase 2a study.
- Quality of weight loss (body composition): evidence suggests a greater reduction in fat mass, without a disproportionate increase in lean mass loss, in body-composition sub-studies.
- Tolerability profile consistent with the incretin class, with gastrointestinal events most commonly reported in studies (e.g., nausea, diarrhoea, and constipation).
Mechanism of Action
Retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors. This combination works in an integrated manner to reduce appetite and increase satiety, improve glycaemic homeostasis, and promote greater energy expenditure/thermogenesis via activity at the glucagon receptor.
Key Benefits
– Marked reduction in body weight in clinical studies, with high-impact results in obesity.
– Improved glycaemic control and cardiometabolic markers (e.g., inflammatory lipids and blood pressure reported in readouts).
– Reduction in liver fat and improvements associated with metabolic liver disease (MASLD/MASH) in a Phase 2a study.
– Quality of weight loss (body composition): evidence suggests a greater reduction in fat mass, without a disproportionate increase in lean mass loss, in body-composition sub-studies.
– Tolerability profile consistent with the incretin class, with gastrointestinal events most commonly reported in studies (e.g., nausea, diarrhoea, and constipation).
Technical Details
Item Weight
Product Dimensions
Item model number
Item Package Quantity
Number of Handles
Batteries Required?
DOSING USED IN PHASE 3 STUDIES
In the most recent studies from the TRIUMPH programme (Phase 3), retatrutide was administered as follows:
-
Route: Subcutaneous
-
Frequency: Once weekly
-
Study duration: Approximately 68 weeks
Recommended Dosage (Clinical Research Escalation Model)
Retatrutide is administered once weekly using a gradual dose escalation to improve tolerability.
Dose Escalation Structure
Phase Weekly Dose
Weeks 1–4 1 mg
Weeks 5–8 2 mg
Weeks 9–12 4 mg
Maintenance (research range) 6–8 mg
Clinical trials have evaluated doses up to 12 mg once weekly with gradual titration.
Related Products
NAD+ (500mg)
NAD+ (nicotinamide adenine dinucleotide) is a naturally occurring coenzyme found in virtually every cell of the body. It plays a central role in cellular energy production, mitochondrial function, DNA repair, and cellular signaling. As we age, NAD+ availability tends to decline, which has driven growing scientific interest in its role in healthy aging, cellular resilience, and metabolic function.
Key Benefits
Cellular energy support, contributing to efficient mitochondrial function and energy production.
Support for cellular repair and maintenance, participating in processes involved in DNA repair and cellular homeostasis.
Mitochondrial function, helping support the systems responsible for maintaining cellular energy and resilience.
Cellular protection, contributing to the body’s response to oxidative stress and cellular damage.
Healthy aging support, supporting cellular function and resilience as part of advanced longevity and wellness protocols.
GHK-CU (100mg)
GHK-Cu is a bioactive complex formed by the tripeptide GHK bound to copper (II). It is a molecule naturally present in the body, known for supporting cellular renewal, tissue repair, and skin integrity. With age, its levels tend to decline, which has driven its use in advanced aesthetic and regenerative protocols.
Key Benefits
Firmer, more elastic, denser skin, with a more “filled” and healthy appearance.
Improved texture and radiance, with softening of fine lines and a more even look.
Support for skin repair and recovery, helping maintain cutaneous integrity after external stressors.
Cellular protection, helping regulate inflammatory processes and the impact of oxidative stress.
Overall improved skin quality, supporting a revitalised and rejuvenated appearance throughout the protocol.
Tirzepatide (60mg)
Intelligent metabolic regulation for consistent weight loss.
Tirzepatide is a dual agonist of GIP and GLP-1 receptors, acting in an integrated way across incretin pathways.It increases insulin secretion in a glucose-dependent manner and improves glycaemic regulation (reducing peaks and variability).
It acts on appetite/satiety centres, helping to reduce food intake and supporting adherence to body recomposition strategies.
Key Benefits
- Significant reduction in body weight in studies involving people with obesity/overweight (results depend on dose, duration, and adherence).
- Robust improvement in glycaemic control (HbA1c) in people with type 2 diabetes, with dose-dependent reductions observed in clinical trials.
- Cardiometabolic improvements associated with weight loss and incretin pathway activity.
- Maintenance of weight loss with continued treatment, demonstrating sustained outcomes when use is maintained within protocol (in maintenance trials).
Retatrutide (40mg)
Mechanism of Action
Retatrutide is a triple agonist of GLP-1, GIP, and glucagon receptors. This combination works in an integrated manner to reduce appetite and increase satiety, improve glycaemic homeostasis, and promote greater energy expenditure/thermogenesis via activity at the glucagon receptor.
Key Benefits
– Marked reduction in body weight in clinical studies, with high-impact results in obesity.
– Improved glycaemic control and cardiometabolic markers (e.g., inflammatory lipids and blood pressure reported in readouts).
– Reduction in liver fat and improvements associated with metabolic liver disease (MASLD/MASH) in a Phase 2a study.
– Quality of weight loss (body composition): evidence suggests a greater reduction in fat mass, without a disproportionate increase in lean mass loss, in body-composition sub-studies.
– Tolerability profile consistent with the incretin class, with gastrointestinal events most commonly reported in studies (e.g., nausea, diarrhoea, and constipation).
